نتایج جستجو برای: overall response rate orr

تعداد نتایج: 2165667  

2014
Michinori Ogura Kiyoshi Ando Tatsuya Suzuki Kenichi Ishizawa Sung Yong Oh Kuniaki Itoh Kazuhito Yamamoto Wing Yan Au Hwei-Fang Tien Yoshihiro Matsuno Takashi Terauchi Keiko Yamamoto Masahiko Mori Yoshinobu Tanaka Takashi Shimamoto Kensei Tobinai Won Seog Kim

Although initial rituximab-containing chemotherapies achieve high response rates, indolent B-cell non-Hodgkin lymphoma (B-NHL), such as follicular lymphoma (FL), is still incurable. Therefore, new effective agents with novel mechanisms are anticipated. In this multicentre phase II study, patients with relapsed/refractory indolent B-NHL and mantle cell lymphoma (MCL) received vorinostat 200 mg t...

2018
Zhibo Xie Yifan Zhang Chen Jin Deliang Fu

This meta-analysis was designed to compare the efficacy and safety of gemcitabine-based regimens for the treatment advanced breast cancer (ABC). Altogether 15 studies involving 8195 ABC patients were retrieved for analysis. Compared with non-gemcitabine-based chemotherapies, patients receiving gemcitabine-based therapy exhibited better overall survival (OS), progression free survival (PFS), and...

2017
Yan Shi Sui Zhang Quanli Han Jie Li Huan Yan Yao Lv Huaiyin Shi Rong Liu Guanghai Dai

This single-arm, phase II trial is to investigate efficacy and safety of nab-paclitaxel plus S-1 as first-line treatment in advanced pancreatic cancer. Nab-paclitaxel was administered at 120 mg/m2 intravenously on day 1 and 8, S-1 was given twice a day orally on day 1-14 of each 21-day cycle, for 6 cycles. The primary endpoint was objective response rate (ORR), the secondary endpoints were prog...

2012
Yue Ma Ying-Chun Xu Lei Tang Zan Zhang Jian Wang Hong-Xia Wang

UNLABELLED PURPOSE To evaluate the efficacy of cytokine-induced killer (CIK) cell therapy in the treatment of hepatocellular carcinoma. MATERIALS AND METHODS Randomized phase II and III trials on CIK cell-based therapy were identified by electronic searches using a combination of "hepatocellular carcinoma" and "cytokine-induced killer cells". RESULTS The analysis showed significant survi...

2016
Yali Han Jie Liu Meili Sun Zongpu Zhang Chuanyong Liu Yuping Sun

BACKGROUND There is no definitive conclusion so far on the predictive values of ERCC1 polymorphisms for clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). We updated this meta-analysis with an expectation to obtain some statistical advancement on this issue. METHODS Relevant studies were identified by searching MEDLINE, EMBASE databases from inception to A...

Journal: :International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2012
Takeshi Ishikawa Satoshi Kokura Naoyuki Sakamoto Takashi Ando Eiko Imamoto Takeshi Hattori Hirokazu Oyamada Naomi Yoshinami Masafumi Sakamoto Kazutomo Kitagawa Yoko Okumura Naohisa Yoshida Kazuhiro Kamada Kazuhiro Katada Kazuhiko Uchiyama Osamu Handa Tomohisa Takagi Hiroaki Yasuda Junichi Sakagami Hideyuki Konishi Nobuaki Yagi Yuji Naito Toshikazu Yoshikawa

PURPOSE Despite advances in cancer therapy, treating pancreatic cancer remains one of the major challenges in the field of medical oncology. We conducted this phase II study to evaluate the efficacy and safety of regional hyperthermia combined with gemcitabine for the treatment of unresectable advanced pancreatic cancer. METHODS Eligibility criteria included histologically proven, locally adv...

2016
Hui Zhan Yang Yang Bing Zhao Shuguang Hao Xiabao Hou

Objective: To summarize and compare the therapeutic efficacy of programmed death 1 (PD-1) and cytotoxic T lymphocyte associated antigen 4 (CTLA-4) pathway inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Methods: Traditional and network meta-analysis of clinical phase II/III randomized controlled trials of PD-1 and CTLA-4 pathway inhibitors vs. controls (general chemotherapy o...

2016
Yue Yang Haitao Wu Jian Zhou

BACKGROUND This research aims to assess the response to acid suppression therapy in gastroesophageal reflux disease (GERD)-related chronic laryngitis (CL). METHODS Data were extracted from Web of Knowledge, Embase, and PubMed for English language article published up to March 2016. Pooled overall response rate (ORR) rates were evaluated to determine acid suppression treatment efficacy. Random...

Journal: :Blood 2015
Xavier Leleu Lionel Karlin Margaret Macro Cyrille Hulin Laurent Garderet Murielle Roussel Bertrand Arnulf Brigitte Pegourie Brigitte Kolb Anne Marie Stoppa Sabine Brechiniac Gerald Marit Beatrice Thielemans Brigitte Onraed Claire Mathiot Anne Banos Laurence Lacotte Mourad Tiab Mamoun Dib Jean-Gabriel Fuzibet Marie Odile Petillon Philippe Rodon Marc Wetterwald Bruno Royer Laurence Legros Lotfi Benboubker Olivier Decaux Martine Escoffre-Barbe Denis Caillot Jean Paul Fermand Philippe Moreau Michel Attal Herve Avet-Loiseau Thierry Facon

The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be safely administered to patients with end-stage relapsed/refractory multiple myeloma (RRMM). However, we observed a shorter median progression-free survival (PFS) and overall survival (OS) in these patients when characterized with adverse cytogenetics (deletion 17p and translocation [4;14]) in the Intergroupe Francophone...

2017
Francisco Bautista Victoria Fioravantti Teresa de Rojas Fernando Carceller Luis Madero Alvaro Lassaletta Lucas Moreno

Survival rates for patients with medulloblastoma have improved in the last decades but for those who relapse outcome is dismal and new approaches are needed. Emerging drugs have been tested in the last two decades within the context of phase I/II trials. In parallel, advances in genetic profiling have permitted to identify key molecular alterations for which new strategies are being developed. ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید